Free Radical Research,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 14
Published: Jan. 20, 2025
PurposeThe
concept
of
dual-state
hyper-energy
metabolism
characterized
by
elevated
glycolysis
and
OxPhos
has
gained
considerable
attention
during
tumor
growth
metastasis
in
different
malignancies.
However,
it
is
largely
unknown
how
such
metabolic
phenotypes
influence
the
radiation
response
aggressive
cancers.
Therefore,
present
study
aimed
to
investigate
impact
(increased
OxPhos)
on
a
human
glioma
cell
line.MethodsModulation
mitochondrial
electron
transport
chain
was
carried
out
using
2,4-dinitrophenol
(DNP).
Metabolic
characterization
assessing
glucose
uptake,
lactate
production,
mass,
membrane
potential,
ATP
production.
The
examined
growth,
clonogenic
survival,
death
assays.
Macromolecular
oxidation
assessed
DNA
damage,
lipid
peroxidation,
protein
carbonylation
assay.ResultsHypermetabolic
OPM-BMG
cells
exhibited
significant
increase
following
irradiation
as
compared
parental
BMG-1
cells.
Enhanced
radioresistance
evidenced
α/β
ratio
(9.58)
D1
dose
(4.18
Gy)
4.36
2.19
Gy
respectively.
Moreover,
were
found
exhibit
increased
resistance
against
radiation-induced
death,
macromolecular
Inhibition
complex-II
significantly
enhanced
radiosensitivity
cells.ConclusionOur
results
demonstrate
that
confer
radioresistance.
Consequently
targeting
combination
with
may
overcome
therapeutic
cancers
like
glioma.
Pharmacological Reports,
Journal Year:
2023,
Volume and Issue:
75(4), P. 876 - 890
Published: June 19, 2023
Abstract
Although
Warburg's
discovery
of
intensive
glucose
uptake
by
tumors,
followed
lactate
fermentation
in
oxygen
presence
was
made
a
century
ago,
it
is
still
an
area
intense
research
and
development
new
hypotheses
that,
layer
layer,
unravel
the
complexities
neoplastic
transformation.
This
seemingly
simple
metabolic
reprogramming
cancer
cells
reveals
intriguing,
multi-faceted
nature
that
may
link
various
phenomena
including
cell
signaling,
proliferation,
ROS
generation,
energy
supply,
macromolecules
synthesis/biosynthetic
precursor
immunosuppression,
or
cooperation
cancerous
with
cancer-associated
fibroblasts
(CAFs),
known
as
reversed
Warburg
effect.
According
to
current
perception
causes
consequences
effect,
PI3K/Akt/mTOR
are
main
signaling
pathways
concert
transcription
factors
HIF-1,
p53,
c-Myc,
modulate
activity/expression
key
regulatory
enzymes,
PKM2,
PDK1
tune
most
optimal
setting
for
cell.
turn
secures
adequate
levels
biosynthetic
precursors,
NADPH,
NAD
+
,
rapid
ATP
production
meet
increased
demands
intensively
proliferating
tumor
cells.
The
end-product
“aerobic
glycolysis”,
lactate,
oncometabolite,
provide
fuel
neighboring
cells,
facilitate
metastasis
immunosuppression
together
enabling
progression.
importance
possible
applicability
presented
issue
best
illustrated
numerous
trials
agents
targeting
constituting
promising
strategy
future
anti-cancer
regimens.
In
this
review,
we
present
aspects
multifactorial
phenomenon,
depicting
mechanisms
benefits
behind
also
pointing
selected
field
anticancer
therapy.
Experimental Hematology and Oncology,
Journal Year:
2024,
Volume and Issue:
13(1)
Published: Jan. 29, 2024
Abstract
Metabolic
reprogramming
is
an
emerging
hallmark
of
cancer
cells,
enabling
them
to
meet
increased
nutrient
and
energy
demands
while
withstanding
the
challenging
microenvironment.
Cancer
cells
can
switch
their
metabolic
pathways,
allowing
adapt
different
microenvironments
therapeutic
interventions.
This
refers
heterogeneity,
in
which
cell
populations
use
pathways
sustain
survival
proliferation
impact
response
conventional
therapies.
Thus,
targeting
heterogeneity
represents
innovative
avenue
with
potential
overcome
treatment
resistance
improve
outcomes.
review
discusses
patterns
developmental
stages,
summarizes
molecular
mechanisms
involved
intricate
interactions
within
metabolism,
highlights
clinical
vulnerabilities
as
a
promising
regimen.
We
aim
unravel
complex
characteristics
develop
personalized
approaches
address
distinct
traits,
ultimately
enhancing
patient
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Jan. 29, 2024
Cancer,
a
disease
that
modern
medicine
has
not
fully
understood
and
conquered,
with
its
high
incidence
mortality,
deprives
countless
patients
of
health
even
life.
According
to
global
cancer
statistics,
there
were
an
estimated
19.3
million
new
cases
nearly
10
deaths
in
2020,
the
age-standardized
mortality
rates
201.0
100.7
per
100,000,
respectively.
Although
remarkable
advancements
have
been
made
therapeutic
strategies
recently,
overall
prognosis
remains
optimistic.
Consequently,
are
still
many
severe
challenges
be
faced
difficult
problems
solved
therapy
today.
Epigallocatechin
gallate
(EGCG),
natural
polyphenol
extracted
from
tea
leaves,
received
much
attention
for
antitumor
effects.
Accumulating
investigations
confirmed
EGCG
can
inhibit
tumorigenesis
progression
by
triggering
apoptosis,
suppressing
proliferation,
invasion,
migration,
altering
tumor
epigenetic
modification,
overcoming
chemotherapy
resistance.
Nevertheless,
regulatory
roles
biomolecular
mechanisms
immune
microenvironment,
metabolic
immunotherapy
remain
obscure.
In
this
article,
we
summarized
most
recent
updates
about
effects
on
microenvironment
(TME),
reprogramming,
anti-cancer
immunotherapy.
The
results
demonstrated
promote
response
cytotoxic
lymphocytes
dendritic
cells
(DCs),
attenuate
immunosuppression
myeloid-derived
suppressor
(MDSCs)
T
(Tregs),
tumor-promoting
functions
tumor-associated
macrophages
(TAMs),
neutrophils
(TANs),
various
stromal
including
cancer-associated
fibroblasts
(CAFs),
endothelial
(ECs),
stellate
cells,
mesenchymal
stem/stromal
(MSCs).
Additionally,
suppress
multiple
reprogramming
pathways,
glucose
uptake,
aerobic
glycolysis,
glutamine
metabolism,
fatty
acid
anabolism,
nucleotide
synthesis.
Finally,
EGCG,
as
immunomodulator
checkpoint
blockade,
enhance
immunotherapeutic
efficacy
may
promising
candidate
conclusion,
plays
versatile
TME
which
provides
novel
insights
combined
Antioxidants,
Journal Year:
2025,
Volume and Issue:
14(1), P. 94 - 94
Published: Jan. 15, 2025
Normal
tissues
typically
maintain
partial
oxygen
pressure
within
a
range
of
3–10%
oxygen,
ensuring
homeostasis
through
well-regulated
supply
and
responsive
vascular
network.
However,
in
solid
tumors,
rapid
growth
often
outpaces
angiogenesis,
creating
hypoxic
microenvironment
that
fosters
tumor
progression,
altered
metabolism
resistance
to
therapy.
Hypoxic
regions
experience
uneven
distribution
with
severe
hypoxia
the
core
due
poor
vascularization
high
metabolic
consumption.
Cancer
cells
adapt
these
conditions
shifts,
predominantly
relying
on
glycolysis,
by
upregulating
antioxidant
defenses
mitigate
reactive
species
(ROS)-induced
oxidative
damage.
Hypoxia-induced
ROS,
resulting
from
mitochondrial
dysfunction
enzyme
activation,
exacerbates
genomic
instability,
aggressiveness,
therapy
resistance.
Overcoming
hypoxia-induced
ROS
cancer
requires
multifaceted
approach
targets
various
aspects
biology.
Emerging
therapeutic
strategies
target
resistance,
focusing
hypoxia-inducible
factors,
levels,
subpopulations.
Combining
innovative
therapies
existing
treatments
holds
promise
for
improving
outcomes
overcoming
mechanisms.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(25)
Published: April 4, 2024
Glycolysis-dominant
metabolic
pathway
in
cancer
cells
can
promote
their
therapeutic
resistance
against
radiotherapy
(RT).
Carbon
monoxide
(CO)
as
a
glycolysis
inhibitor
enhance
the
efficiency
of
RT.
Herein,
an
X-ray
responsive
CO-releasing
nanocomposite
(HA@AuNC@CO)
based
on
strong
host-guest
interactions
between
radiosensitizer
and
CO
donor
for
enhanced
RT
is
developed.
The
encapsulated
gold
nanoclusters
(CD-AuNCs)
effectively
generate
cytotoxic
reactive
oxygen
species
(ROS)
under
radiation,
which
not
only
directly
inactivate
but
also
induce
situ
gas
generation
from
adamantane
modified
metal
carbonyl
(Ada-CO)
inhibition.
Both
vitro
vivo
results
demonstrate
that
HA@AuNC@CO
exhibits
active
targeting
toward
CD44
overexpressed
cells,
along
with
excellent
inhibition
efficient
cancer.
This
study
offers
new
strategy
combination
therapy
tumor
treatment.
Cancer Letters,
Journal Year:
2024,
Volume and Issue:
589, P. 216824 - 216824
Published: March 23, 2024
Immunotherapy,
especially
immune
checkpoint
inhibitors,
has
revolutionized
clinical
practice
within
the
last
decade.
However,
primary
and
secondary
resistance
to
immunotherapy
is
common
in
patients
with
diverse
types
of
cancer.
It
well-acknowledged
that
tumor
cells
can
facilitate
formation
immunosuppressive
microenvironments
via
metabolism
reprogramming,
lactic
acid,
metabolite
glycolysis,
a
significant
contributor.
SLC16A3
(also
named
as
MCT4)
transporter
mediating
acid
efflux.
In
this
study,
we
investigated
role
glycolysis
aimed
improve
effects
Slc16a3
inhibition.
Bioinformatical
analysis
revealed
expression
glycolysis-related
genes
correlated
less
CD8
Autophagy,
Journal Year:
2024,
Volume and Issue:
20(12), P. 2655 - 2676
Published: July 25, 2024
Spautin-1
is
a
well-known
macroautophagy/autophagy
inhibitor
via
suppressing
the
deubiquitinases
USP10
and
USP13
promoting
degradation
of
PIK3C3/VPS34-BECN1
complex,
while
its
effect
on
selective
autophagy
remains
poorly
understood.
Mitophagy
form
for
removal
damaged
superfluous
mitochondria
autophagy-lysosome
pathway.
Here,
we
report
surprising
discovery
that,
spautin-1
as
an
effective
inhibitor,
it
promotes
PINK1-PRKN-dependent
mitophagy
induced
by
mitochondrial
damage
agents.
Mechanistically,
facilitates
stabilization
activation
full-length
PINK1
at
outer
membrane
(OMM)
binding
to
components
TOMM
complex
(TOMM70
TOMM20),
leading
disruption
import
prevention
PARL-mediated
cleavage.
Moreover,
induces
neuronal
in